An open label study to evaluate long-term safety and efficacy of canakinumab in patients with active, recurrent or chronic TNF receptor-associated periodic syndrome

Trial Profile

An open label study to evaluate long-term safety and efficacy of canakinumab in patients with active, recurrent or chronic TNF receptor-associated periodic syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Familial autosomal dominant periodic fever
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top